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The role of glutamate N-methyl-D-aspartate receptor (NMDAR) hypofunction has been
extensively studied in schizophrenia; however, less is known about its role in anxiety
disorders. Recently, it was demonstrated that astrocytic GLT-1 blockade leads to
an anxiety-like phenotype. Although astrocytes are capable of modulating NMDAR
activity through glutamate uptake transporters, the relationship between astrocytic
glutamate uptake and the development of an anxiety phenotype remains poorly
explored. Here, we aimed to investigative whether long-term antagonism of NMDAR
impacts anxiety-related behaviors and astrocytic glutamate uptake. Memantine, an
NMDAR antagonist, was administered daily for 24 days to healthy adult CF-1 mice by
oral gavage at doses of 5, 10, or 20 mg/kg. The mice were submitted to a sequential
battery of behavioral tests (open field, light–dark box and elevated plus-maze tests).
We then evaluated glutamate uptake activity and the immunocontents of glutamate
transporters in the frontoparietal cortex and hippocampus. Our results demonstrated
that long-term administration of memantine induces anxiety-like behavior in mice in
the light–dark box and elevated plus-maze paradigms. Additionally, the administration
of memantine decreased glutamate uptake activity in both the frontoparietal cortex
and hippocampus without altering the immunocontent of either GLT-1 or GLAST.
Remarkably, the memantine-induced reduction in glutamate uptake was correlated
with enhancement of an anxiety-like phenotype. In conclusion, long-term NMDAR
antagonism with memantine induces anxiety-like behavior that is associated with
reduced glutamate uptake activity but that is not dependent on GLT-1 or GLAST protein
expression. Our study suggests that NMDAR and glutamate uptake hypofunction may
contribute to the development of conditions that fall within the category of anxiety
disorders.
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Introduction
Anxiety disorders are among the most prevalent psychiatric
conditions worldwide. These disorders have been associated
with social isolation, alcoholism, and increased suicide attempts
and are also considered to be risk factors for the development
of additional psychiatric disorders (Gross and Hen, 2004).
Hence, it is imperative to understand the neurobiological
mechanisms that are associated with anxiety disorders. It has
recently been proposed that a functional imbalance of the
tripartite glutamatergic synapse plays a role in anxiety disorders
(Clement and Chapouthier, 1998; Nutt and Malizia, 2001;
Nemeroﬀ, 2003; Machado-Vieira et al., 2009, 2012). Indeed,
glutamatergic neurotransmission oﬀers multiple potential
pharmacological targets for treating anxiety-related disorders,
such as postsynaptic receptor signaling, presynaptic glutamate
release, and astrocytic glutamate uptake (Szabo et al., 2009;
Zarate et al., 2010; Riaza Bermudo-Soriano et al., 2012; Pilc et al.,
2013).
Currently, antagonism of N-methyl-D-aspartate receptor
(NMDAR) has been proposed as a feasible strategy for
reducing the major symptoms that are linked to anxiety-like
behavior (Cortese and Phan, 2005). Indeed, when memantine,
an NMDAR antagonist, is administered to patients presenting
with depression, anxiety or obsessive-compulsive disorder, their
neuropsychiatric symptoms appear to be relieved (Tariot et al.,
2004; Sani et al., 2012). By contrast, a recent work demonstrated
that chronic antagonism of NMDAR induces elevated anxiety
in healthy mice (Hanson et al., 2014). Overall, the current data
that are available regarding the association between the use of
NMDAR antagonists and the presentation of anxiety-related
behaviors refute a simple model of dose-eﬀect and instead seem
to be closely related to the regimen, type of drug, or route of
administration (Silvestre et al., 1997; Riaza Bermudo-Soriano
et al., 2012; Schwartz et al., 2012). Additionally, it is prudent
to consider that glutamatergic neurotransmission involves not
only neuronal receptors (ionotropic and metabotropic) but
also astroglial transporters that participate in neuron-astrocyte
coupling.
Two major astroglial Na+-dependent glutamate transporters,
glutamate transporter 1 (GLT-1, also known as EAAT2) and
glutamate aspartate transporter (GLAST, also known as EAAT1),
take up glutamate from synapses to maintain the homeostasis
that is necessary to orchestrate the physiological activity of
receptors (Danbolt, 2001). Remarkably, cerebral GLT-1 and
GLAST are predominately localized in astrocytes, with very
low expression in other cell types (Zhou and Danbolt, 2014).
Moreover, astrocytes account for 95% of the glutamate uptake
activity in the brain (Danbolt et al., 1992; Lehre and Danbolt,
1998). Importantly, a recent work demonstrated that cerebral
microinjection of the GLT-1 inhibitor, dihydrokainic acid (DHK),
induced anhedonia and anxiety in rats (John et al., 2015).
Thus, one could claim that astrocytic dysfunction may have a
considerable impact on the expression of anxiety-like phenotypes
(Bechtholt-Gompf et al., 2010; Schroeter et al., 2010; Lee et al.,
2013). Based on the principles of neuron-astrocyte coupling,
we hypothesized that long-term antagonism of NMDAR would
impact astrocytic function and that this would likely aﬀect anxiety
phenotype.
In this study, we aimed to investigate the impact of
long-term NMDAR antagonism by memantine on anxiety-
related paradigms and their potential association with astrocytic
glutamate transport.
Materials and Methods
Animals
Three-month-old CF-1 mice were housed in standard cages
(48 cm × 26 cm). The animals were kept in a room with
controlled temperature (22◦C) under a 12 h light/12 h dark
cycle (lights on at 7 am) and had free access to food and water.
The mice (n = 40) were randomized into four groups: control
(CO), memantine 5 mg (MN5), memantine 10 mg (MN10),
and memantine 20 mg (MN20). To avoid social isolation, we
maintained two animals per cage (Leasure and Decker, 2009).
All behavioral tests were performed between 1:00 pm and 5:00
pm. All experiments were conducted in accordance with oﬃcial
governmental guidelines in compliance with the Federation of
Brazilian Societies for Experimental Biology and were approved
by the Ethical Committee of the Federal University of Rio Grande
do Sul, Brazil.
Drug Administration
Memantine (Sigma, USA) was dissolved in distilled water at three
diﬀerent concentrations (0.5, 1.0, and 2.0 mg/mL) to standardize
the volume used for oral administration and reach the desired
dose. For 24 days, the animals received daily administration of
either 5, 10, or 20 mg/kg of memantine, or an equivalent volume
of distilled water, via oral gavage. Body weight and food intake
were monitored. All groups received oral gavage at 1 h after each
behavioral task.
Open Field Test
On the 22nd day, the animals were submitted to an open ﬁeld
task to evaluate spontaneous locomotion and exploratory activity.
The apparatus was made of a black-painted box measuring
50 cm × 50 cm and was surrounded by 50 cm high walls. The
experiments were conducted in a quiet room under low-intensity
light (12 lx). Each mouse (n = 10 per group) was placed in the
center of the arena, and the distance traveled (total and central
zone), time spent in the central zone, and mean speed were
measured over a course of 10 min (Muller et al., 2012). The
experiment was recorded with a video camera that was positioned
above the arena. The analysis was performed using a computer-
operated tracking system (Any-maze, Stoelting, Woods Dale, IL,
USA).
Light–Dark Task
On the 23rd day, the light–dark task was performed as previously
described (Crawley andGoodwin, 1980) with somemodiﬁcations
to analyze anxiety proﬁles. The light–dark apparatus consisted
of a wood rectangular box with two separated chambers. One
chamber had black walls and ﬂoor (50 cm × 50 cm × 50 cm)
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and was not illuminated. The other side had white walls and ﬂoor
(50 cm × 50 cm × 50 cm) and was illuminated by a 100 W
white lamp that was placed overhead. The two compartments
were separated by a wall, which had a small opening at ﬂoor
level. For each experiment, an animal (n = 10 per group) was
initially placed in the white chamber and then allowed to explore
the two-chamber area for a duration of 5 min. The following
parameters were recorded by a trained and blinded-to-treatment
observer: number of transitions between the two chambers, time
spent in the light chamber, and risk assessment behavior. After
each experiment, the apparatus was cleaned with 70% alcohol and
dried before being used with the next animal.
Elevated Plus-Maze Task
On the 24th day, the animals were submitted to an elevated
plus-maze task to evaluate further signs of anxiety-like behavior.
The elevated plus-maze was performed as previously described
(Pellow, 1986). The elevated plus-maze apparatus consisted of
two open arms (30 cm × 5 cm) and two enclosed arms
(30 cm × 5 cm × 10 cm), which were separated by a central
platform (5 cm × 5 cm) with the two identical arms of each type
being placed opposite to each other. The height of the maze was
70 cm, and the experiments were conducted under dim red light
in a quiet room. Each mouse (n = 10 per group) was individually
placed onto the central platform of the plus-maze, facing one
of the open arms, and was observed/recorded for 5 min by a
trained and blinded-to-treatment observer. The time spent in the
open arms and the total distance traveled were used for further
analysis. After each session, the maze was cleaned with 70%
ethanol. Data analysis was performed using a computer-operated
tracking system (Any-maze, Stoelting, Woods Dale, IL, USA).
Glutamate Uptake Assay
On the 25th day, the animals (n = 6 per group) were
sacriﬁced/dissected and left hippocampal and left frontoparietal
cortical brain slices were taken for use in a glutamate uptake
assay. The glutamate uptake assay was performed according to
Thomazi et al. (2004). Brain hippocampal and frontoparietal
cortical slices (0.4 mm) were obtained using a McIlwain tissue
chopper and were pre-incubated for 15 min at 37◦C in Hank’s
balanced salt solution (HBSS), containing 137 mM NaCl,
0.63 mM Na2HPO4, 4.17 mM NaHCO3, 5.36 mM KCl, 0.44 mM
KH2PO4, 1.26 mM CaCl2, 0.41 mM MgSO4, 0.49 mM MgCl2,
and 1.11mMglucose, at pH 7.2. Afterward, 0.66 and 0.33 Ciml−1
L-[3H]glutamate were added to a ﬁnal 100 M concentration of
glutamate for incubation with hippocampal and cortical samples,
respectively. The incubations were stopped after 5 and 7 min
for the hippocampal and cortical samples, respectively, with two
ice-cold washes of 1 ml HBSS, which were immediately followed
by the addition of 0.5 N NaOH. The samples were kept in this
solution overnight. Nonspeciﬁc uptake was measured using the
same protocol as described above, with diﬀerences in temperature
(4◦C) and medium composition (N-methyl-D-glucamine instead
of sodium chloride). Na+-dependent uptake was considered as
the diﬀerence between the total uptake and the non-speciﬁc
uptake. Note that astrocytic transport mediated by GLAST and
GLT-1 is responsible for the Na+-dependent glutamate uptake
(Anderson and Swanson, 2000). Both uptakes were performed in
triplicate. Any radioactivity that was incorporated into the slices
was measured using a liquid scintillation counter.
Western Blotting
For western blot analysis, right hippocampal and right
frontoparietal cortical homogenates (n = 6, per group)
were prepared in PIK buﬀer (1% NP-40, 150 mM NaCl, 20 mM
Tris, pH 7.4, 10% glycerol, 1 mM CaCl2, 1 mM MgCl2, 400 μM
sodium vanadate, 0.2 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml
aprotinin, and 0.1% phosphatase inhibitor cocktails I and II
from Sigma–Aldrich) and centrifuged (Zimmer et al., 2012).
Supernatants were collected and total protein was measured
using Peterson’s method (Peterson, 1977). Samples containing
20 μg of protein from the hippocampal homogenate were
separated by electrophoresis on a polyacrylamide gel and
electrotransferred to PVDF membranes. Protein bands within
each sample lane were compared to standard molecular weight
markers (Precision Plus ProteinTM Dual Color Standards,
Bio-Rad), which were used to identify the molecular weights
of proteins of interest. Non-speciﬁc binding sites were blocked
using Tween–Tris buﬀered saline (TTBS, 100 mM Tris–HCl,
pH 7.5) with 5% albumin for 2 h. Samples were incubated
overnight at 4◦C with primary antibodies against GLT-1 (Abcam,
1:1000), GLAST (Abcam, 1:1000), and β-actin (Sigma, 1:5000).
Following primary antibody incubation, the membranes were
incubated with secondary antibodies (anti-rabbit, GE life
sciences, 1:3000; anti-mouse, GE life sciences, 1:5000) for 2 h at
room temperature. Films were scanned, and band intensity was
analyzed using Image J software (Abramoﬀ et al., 2004).
Statistical Analysis
Diﬀerences between groups were analyzed with analysis of
variance (ANOVA) followed by Tukey’s post hoc test. Correlations
between behavioral assessments and glutamate uptake were
analyzed by Pearson’s correlation coeﬃcient. The results are
presented as mean values ± SEM. Diﬀerences were considered
signiﬁcant at p< 0.05.
Results
Long-Term NMDAR Antagonism does not Alter
Spontaneous Locomotion but Induces
Anxiety-Like Behavior
Administration of memantine did not cause signiﬁcant changes
in either distance traveled [Figure 1A; F(3,36) = 1.642,
p = 0.1967] or time spent in the central zone [Figure 1B;
F(3,36) = 0.1697, p = 0.9162] in the open ﬁeld. Occupancy plots
are used to illustrate the similarities between groups in the open
ﬁeld test (Figure 1C).
Long-Term NMDAR Antagonism Reduced
Time Spent in the Light Compartment of the
Light–Dark Box
In the light–dark box (Figure 1G), all of the doses of memantine
that were tested signiﬁcantly reduced the time spent in the light
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compartment by the memantine-administered mice compared to
the CO group [Figure 1D; F(3,36) = 7.364, MN5: p= 0.03, MN10:
p = 0.002, MN20: p = 0.01]. However, transition numbers (light
to dark) were unrelated tomemantine administration [Figure 1E;
F(3,36) = 0.8257, p = 0.4884]. Additionally, there were no
diﬀerences among groups in risk assessment index [Figure 1F;
F(3,36) = 1.129, p = 0.3519].
Long-Term NMDAR Antagonism Decreased
Time Spent in the Open Arms of the Elevated
Plus-Maze
The administration of memantine reduced the time spent by
mice in the open arms of the elevated plus-maze (Figure 1J)
when compared to the CO group [Figure 1H; F(3,36) = 6.974,
MN5: p = 0.007, MN10: p = 0.002, MN20: p = 0.004]; however,
there were no changes in total distance traveled [Figure 1I;
F(3,36) = 2.227, p = 0.1018].
Long-Term NMDAR Antagonism Decreased
Glutamate Uptake in the Frontoparietal Cortex
and Hippocampus without Affecting the
Immunocontents of GLAST and GLT-1
The administration of memantine signiﬁcantly decreased
glutamate uptake in slices of frontoparietal cortex [Figure 2A;
F(3,20) = 11.458, MN5: p = 0.026, MN10: p < 0.001, MN20:
p < 0.001] and hippocampus [Figure 2D; F(3,20) = 15.008,
MN5: p = 0.015, MN10: p < 0.001, MN20: p < 0.001]. However,
memantine did not alter the immunocontent of GLAST in
either the frontoparietal cortex [Figure 2B; F(3,20) = 1.300,
p = 0.3020] or the hippocampus [Figure 2E; F(3,20) = 0.6174,
p = 0.6118]. Additionally, no alterations were found in the
immunocontent of GLT-1 in either the frontoparietal cortex
[Figure 2C; F(3,20) = 2.225, p = 0.1167] or the hippocampus
[Figure 2F; F(3,20) = 0.1520, p = 0.9272].
Correlation Between Anxiety-Like Behavior
and Glutamate Uptake
A positive correlation was found between time spent in the light
compartment of the light dark-box and glutamate uptake in the
frontoparietal cortex (Figure 3A; p < 0.0001, R = 0.7289) and
hippocampus (Figure 3C; p = 0.03, R = 0.4337). Time spent in
the open arms of the elevated plus-maze test was also correlated
with glutamate uptake in the frontoparietal cortex (Figure 3B;
p = 0.03, R = 0.4313) and hippocampus (Figure 3D; p = 0.01,
R = 0.4815).
Discussion
Our results demonstrated that long-term antagonism of NMDAR
by memantine induces anxiety-like behavior in healthy CF-
1 mice. Additionally, memantine decreased glutamate uptake
activity in the frontoparietal cortex and in the hippocampus
FIGURE 1 | Long-term NMDAR antagonism does not alter
spontaneous locomotor and exploratory behavior, but induces
anxiety-like behavior. (A) Total distance traveled in the open field.
(B) Time in central zone in the open field. (C) Open field apparatus and
occupancy plots. (D) Time in light compartment in the light–dark box.
(E) Number of transitions in the light–dark box. (F) Risk assessment
index in the light–dark box. (G) Light–dark box apparatus. (H) Time in
open arms in the elevated plus-maze. (I) Distance traveled in the
elevated plus-maze. (J) Elevated plus-maze apparatus and occupancy
plots. Groups: control (CO), memantine 5 mg (MN 5), memantine 10 mg
(MN 10), and memantine 20 mg (MN 20); n = 10 per group. Data are
presented as mean values ± SEM.
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FIGURE 2 | Long-term NMDAR antagonism decreases glutamate uptake
in the frontoparietal cortex and hippocampus, but does not alter
astroglial transporter immunocontent. (A) Glutamate uptake in slices of
frontoparietal cortex. (B) Immunocontent of GLAST in the frontoparietal cortex.
(C) Immunocontent of GLT-1 in the frontoparietal cortex. (D) Glutamate uptake
in slices of hippocampus. (E) Immunocontent of GLAST in the frontoparietal
cortex. (F) Immunocontent of GLT-1T in the frontoparietal cortex. Groups: CO,
memantine 5 mg (MN 5), memantine 10 mg (MN 10), and memantine 20 mg
(MN 20); n = 6 per group. Data are presented as mean values ± SEM.
∗p < 0.05 among groups.
with this phenomenon correlating with anxiety-like behavior.
By contrast, the immunocontents of the astroglial glutamate
transporters GLT-1 and GLAST were not aﬀected.
Long-term administration of memantine did not induce
signiﬁcant changes in the spontaneous locomotion and
exploratory activity of mice in the open ﬁeld test. These ﬁndings
imply that neither the dose nor the regimen of memantine that
was used in our work led to non-speciﬁc eﬀects such as sedation,
which can potentially impair performance in anxiety-like tasks.
This ﬁnding is in agreement with previous reports that have
demonstrated that memantine administration does not alter
locomotion or exploratory proﬁles (Reus et al., 2010). Conversely,
we also showed that long-term memantine administration at
doses of 5, 10, or 20 mg/kg leads to an anxiogenic phenotype that
is manifested by decreased time spent in the light compartment
(light–dark box) and reduced time spent in open arms (elevated
plus-maze). Interestingly, a previous work showed that the
administration of MK801, another non-competitive NMDAR
antagonist, to rats induced an anxiety-like phenotype in the
elevated plus-maze (Solati, 2011). In contrast to MK801, high
doses of memantine (100 mg/kg) increased time spent in open
arms, implying an anxiolytic eﬀect. However, doses ranging from
10 to 30 mg/kg decreased time spent in open arms (∼40%),
without reaching statistical signiﬁcance, which suggests a
trend representative of an anxiogenic-like eﬀect (Minkeviciene
et al., 2008). Additionally, chronic antagonism of NMDAR
with piperine18 exacerbated anxiogenic symptoms in C57BL/6
mice (Hanson et al., 2014). Indeed, it would appear that the
antagonism of NMDAR does not follow a linear dose-response
eﬀect in terms of modulating anxiety-like behavior.
It has also been shown that memantine plays a role
in controlling synaptic glutamate release. In fact, Lu et al.
(2010) have shown that memantine suppresses glutamate
release in cortical synaptosomes. In this study, however, we
showed that long-term administration of memantine reduces
glutamate uptake without aﬀecting the glutamate transporters
expression, GLT-1 and GLAST, in the frontoparietal cortex and
hippocampus. Based on these ﬁndings, one could argue that
memantine-induced reduction of glutamate uptake by astrocytes
is a direct adaptive response to the reduced release of glutamate
by neurons. This assumption reinforces a theoretical framework
in which neurons and astrocytes are capable of sensing each
other while regulating tripartite glutamatergic synapses (Wade
et al., 2013; Karus et al., 2015). However, further studies using
additional methodologies, such as immunostaining and electron
microscopy, are necessary to better understand neuron-astrocyte
coupling in the context of anxiety-like phenotypes.
Interestingly, a recent work demonstrated that blockade of
GLT-1 in the central amygdala was also capable of inducing
anxiety-like behavior, which reinforces the association between
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FIGURE 3 | Anxiety-like behavior correlates with glutamate uptake.
(A) Linear correlation between time spent in light compartment during
the light/dark task and glutamate uptake in slices of frontoparietal
cortex. (B) Linear correlation between time spent in open arms and
glutamate uptake in slices of frontoparietal cortex. (C) Linear correlation
between time spent in light compartment during light/dark task and
glutamate uptake in slices of hippocampus. (D) Linear correlation
between time spent in open arms in elevated plus-maze test and
glutamate uptake in slices of hippocampus. Groups: CO, memantine
5 mg (MN 5), memantine 10 mg (MN 10), and memantine 20 mg
(MN 20); n = 24. Data presented by one animal per point.
∗p < 0.05.
astrocytic glutamate uptake activity and the development of an
anxiety phenotype (John et al., 2015). Remarkably, we were able
to show through linear correlation that decreased glutamate
uptake activity in the hippocampus and frontoparietal cortex was
signiﬁcantly correlated with an increased anxiety-like response.
Conclusion
Long-term NMDAR antagonism by memantine induces an
anxiety phenotype that is associated with reduced glutamate
uptake activity in healthy CF-1 mice, which suggests that
interactions between neurons and astrocytes can shape anxiety-
related behavior.
Author Contributions
EZ was responsible for the design, acquisition, analysis,
interpretation, drafting, and approval of the ﬁnal version of the
manuscript. VT, EK, MA, KZ, RA, and GH were responsible
for acquisition, analysis, interpretation, and approval of the ﬁnal
version of the manuscript. AM, DS, and RV were responsible
for interpretation, drafting, critical revision, and approval of the
ﬁnal version of the manuscript. LVwas responsible for the design,
interpretation, drafting, critical revision, and approval of the ﬁnal
version of the manuscript.
Acknowledgments
This work was supported by the following Brazilian agencies
and grants: National Counsel of Technological and Scientiﬁc
Development (CNPq), CAPES, FAPERGS, Brazilian Institute of
Neuroscience (IBNnet), FINEP, and National Institute of Science
and Technology (INCT) – Excitotoxicity and Neuroprotection.
Supplementary Material
The Supplementary Material for this article can be found online
at: http://journal.frontiersin.org/article/10.3389/fncel.2015.
00219/abstract
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 June 2015 | Volume 9 | Article 219
Zimmer et al. NMDAR links glutamate uptake and anxiety
References
Abramoﬀ, M. D., Magalhaes, P. J., and Ram, S. J. (2004). Processing with ImageJ.
Biophotonics Intern. 11, 36–42.
Anderson, C. M., and Swanson, R. A. (2000). Astrocyte glutamate transport:
review of properties, regulation, and physiological functions. Glia 32, 1–14. doi:
10.1002/1098-1136(200010)32:1<1::AID-GLIA10>3.0.CO;2-W
Bechtholt-Gompf, A. J., Walther, H. V., Adams, M. A., Carlezon, W. A.
Jr., Ongur, D., and Cohen, B. M. (2010). Blockade of astrocytic
glutamate uptake in rats induces signs of anhedonia and impaired spatial
memory. Neuropsychopharmacology 35, 2049–2059. doi: 10.1038/npp.
2010.74
Clement, Y., and Chapouthier, G. (1998). Biological bases of anxiety. Neurosci.
Biobehav. Rev. 22, 623–633. doi: 10.1016/S0149-7634(97)00058-4
Cortese, B. M., and Phan, K. L. (2005). The role of glutamate in anxiety and related
disorders. CNS Spectr. 10, 820–830.
Crawley, J., and Goodwin, F. K. (1980). Preliminary report of a simple animal
behavior model for the anxiolytic eﬀects of benzodiazepines. Pharmacol.
Biochem. Behav. 13, 167–170. doi: 10.1016/0091-3057(80)90067-2
Danbolt, N. C. (2001). Glutamate uptake. Prog. Neurobiol. 65, 1–105. doi:
10.1016/S0301-0082(00)00067-8
Danbolt, N. C., Storm-Mathisen, J., and Kanner, B. I. (1992). An [Na+ +
K+]coupled L-glutamate transporter puriﬁed from rat brain is located in
glial cell processes. Neuroscience 51, 295–310. doi: 10.1016/0306-4522(92)
90316-T
Gross, C., and Hen, R. (2004). The developmental origins of anxiety. Nat. Rev.
Neurosci. 5, 545–552. doi: 10.1038/nrn1429
Hanson, J. E., Meilandt, W. J., Gogineni, A., Reynen, P., Herrington, J., Weimer,
R. M., et al. (2014). Chronic GluN2B antagonism disrupts behavior in wild-
type mice without protecting against synapse loss or memory impairment
in Alzheimer’s disease mouse models. J. Neurosci. 34, 8277–8288. doi:
10.1523/JNEUROSCI.5106-13.2014
John, C. S., Sypek, E. I., Carlezon, W. A., Cohen, B. M., Ongur, D.,
and Bechtholt, A. J. (2015). Blockade of the GLT-1 transporter in the
central nucleus of the amygdala induces both anxiety and depressive-
like symptoms. Neuropsychopharmacology 40, 1700–1708. doi: 10.1038/npp.
2015.16
Karus, C., Mondragao, M. A., Ziemens, D., and Rose, C. R. (2015). Astrocytes
restrict discharge duration and neuronal sodium loads during recurrent
network activity. Glia 63, 936–957. doi: 10.1002/glia.22793
Leasure, J. L., and Decker, L. (2009). Social isolation prevents exercise-induced
proliferation of hippocampal progenitor cells in female rats. Hippocampus 19,
907–912. doi: 10.1002/hipo.20563
Lee, Y., Son, H., Kim, G., Kim, S., Lee, D. H., Roh, G. S., et al. (2013).
Glutamine deﬁciency in the prefrontal cortex increases depressive-like
behaviours in male mice. J. Psychiatry Neurosci. 38, 183–191. doi: 10.1503/jpn.
120024
Lehre, K. P., and Danbolt, N. C. (1998). The number of glutamate transporter
subtype molecules at glutamatergic synapses: chemical and stereological
quantiﬁcation in young adult rat brain. J. Neurosci. 18, 8751–8757.
Lu, C. W., Lin, T. Y., and Wang, S. J. (2010). Memantine depresses glutamate
release through inhibition of voltage-dependent Ca2+ entry and protein kinase
C in rat cerebral cortex nerve terminals: an NMDA receptor-independent
mechanism. Neurochem. Int. 57, 168–176. doi: 10.1016/j.neuint.2010.
05.010
Machado-Vieira, R., Ibrahim, L., Henter, I. D., and Zarate, C. A. Jr. (2012).
Novel glutamatergic agents for major depressive disorder and bipolar
disorder. Pharmacol. Biochem. Behav. 100, 678–687. doi: 10.1016/j.pbb.2011.
09.010
Machado-Vieira, R., Manji, H. K., and Zarate, C. A. (2009). The role of the
tripartite glutamatergic synapse in the pathophysiology and therapeutics
of mood disorders. Neuroscientist 15, 525–539. doi: 10.1177/10738584093
36093
Minkeviciene, R., Banerjee, P., and Tanila, H. (2008). Cognition-enhancing
and anxiolytic eﬀects of memantine. Neuropharmacology 54, 1079–1085. doi:
10.1016/j.neuropharm.2008.02.014
Muller, A. P., Zimmer, E. R., Kalinine, E., Haas, C. B., Oses, J. P., Martimbianco
De Assis, A., et al. (2012). Physical exercise exacerbates memory deﬁcits
induced by intracerebroventricular STZ but improves insulin regulation of
H2O2 production in mice synaptosomes. J. Alzheimers Dis. 30, 889–898. doi:
10.3233/JAD-2012-112066
Nemeroﬀ, C. B. (2003). The role of GABA in the pathophysiology and treatment of
anxiety disorders. Psychopharmacol. Bull. 37, 133–146.
Nutt, D. J., and Malizia, A. L. (2001). New insights into the role of the GABA(A)-
benzodiazepine receptor in psychiatric disorder. Br. J. Psychiatry 179, 390–396.
doi: 10.1192/bjp.179.5.390
Pellow, S. (1986). Anxiolytic and anxiogenic drug eﬀects in a novel test of anxiety:
are exploratory models of anxiety in rodents valid? Methods Find Exp. Clin.
Pharmacol. 8, 557–565.
Peterson, G. L. (1977). A simpliﬁcation of the protein assay method of Lowry
et al. which is more generally applicable. Anal. Biochem. 83, 346–356. doi:
10.1016/0003-2697(77)90043-4
Pilc, A., Wieron´ska, J. M., and Skolnick, P. (2013). Glutamate-based
antidepressants: preclinical psychopharmacology. Biol. Psychiatry 73,
1125–1132. doi: 10.1016/j.biopsych.2013.01.021
Reus, G. Z., Stringari, R. B., Kirsch, T. R., Fries, G. R., Kapczinski, F., Roesler, R.,
et al. (2010). Neurochemical and behavioural eﬀects of acute and chronic
memantine administration in rats: further support for NMDA as a new
pharmacological target for the treatment of depression? Brain Res. Bull. 81,
585–589. doi: 10.1016/j.brainresbull.2009.11.013
Riaza Bermudo-Soriano, C., Perez-Rodriguez, M. M., Vaquero-Lorenzo, C.,
and Baca-Garcia, E. (2012). New perspectives in glutamate and anxiety.
Pharmacol. Biochem. Behav. 100, 752–774. doi: 10.1016/j.pbb.2011.
04.010
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., et al.
(2012). The role of memantine in the treatment of psychiatric disorders other
than the dementias: a review of current preclinical and clinical evidence. CNS
Drugs 26, 663–690. doi: 10.2165/11634390-000000000-00000
Schroeter, M. L., Abdul-Khaliq, H., Sacher, J., Steiner, J., Blasig, I. E., and
Mueller, K. (2010). Mood disorders are glial disorders: evidence from in
vivo studies. Cardiovasc. Psychiatry Neurol. 2010:780645. doi: 10.1155/2010/
780645
Schwartz, T. L., Siddiqui, U. A., and Raza, S. (2012). Memantine as an
augmentation therapy for anxiety disorders. Case Rep. Psychiatry 2012:749796.
doi: 10.1155/2012/749796
Silvestre, J. S., Nadal, R., Pallares, M., and Ferre, N. (1997). Acute eﬀects of
ketamine in the holeboard, the elevated-plus maze, and the social interaction
test in Wistar rats. Depress. Anxiety 5, 29–33. doi: 10.1002/(SICI)1520-
6394(1997)5:1<29::AID-DA5>3.0.CO;2-0
Solati, J. (2011). Dorsal hippocampal N-methyl-d-aspartate glutamatergic and
delta-opioidergic systemsmodulate anxiety behaviors in rats in a noninteractive
manner. Kaohsiung J. Med. Sci. 27, 485–493. doi: 10.1016/j.kjms.2011.
06.011
Szabo, S. T., Machado-Vieira, R., Yuan, P.,Wang, Y.,Wei, Y., Falke, C., et al. (2009).
Glutamate receptors as targets of protein kinase C in the pathophysiology
and treatment of animal models of mania. Neuropharmacology 56, 47–55. doi:
10.1016/j.neuropharm.2008.08.015
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., Mcdonald, S., and
Gergel, I. (2004). Memantine treatment in patients with moderate to severe
Alzheimer disease already receiving donepezil: a randomized controlled trial.
JAMA 291, 317–324. doi: 10.1001/jama.291.3.317
Thomazi, A. P., Godinho, G. F., Rodrigues, J. M., Schwalm, F. D.,
Frizzo, M. E., Moriguchi, E., et al. (2004). Ontogenetic proﬁle of
glutamate uptake in brain structures slices from rats: sensitivity to
guanosine. Mech. Ageing Dev. 125, 475–481. doi: 10.1016/j.mad.2004.
04.005
Wade, J., Mcdaid, L., Harkin, J., Crunelli, V., and Kelso, S. (2013).
Biophysically based computational models of astrocyte ∼ neuron coupling
and their functional signiﬁcance. Front. Comput. Neurosci. 7:44. doi:
10.3389/fncom.2013.00044
Zarate, C. Jr., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N.,
and Salvadore, G. (2010). Glutamatergic modulators: the future of
treating mood disorders? Harv. Rev. Psychiatry 18, 293–303. doi:
10.3109/10673229.2010.511059
Zhou, Y., andDanbolt, N. C. (2014). Glutamate as a neurotransmitter in the healthy
brain. J. Neural. Transm. 121, 799–817. doi: 10.1007/s00702-014-1180-8
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 June 2015 | Volume 9 | Article 219
Zimmer et al. NMDAR links glutamate uptake and anxiety
Zimmer, E. R., Kalinine, E., Haas, C. B., Torrez, V. R., Souza, D. O., Muller,
A. P., et al. (2012). Pretreatment with memantine prevents Alzheimer-like
alterations induced by intrahippocampal okadaic acid administration in rats.
Curr. Alzheimer Res. 9, 1182–1190. doi: 10.2174/156720512804142877
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Zimmer, Torrez, Kalinine, Augustin, Zenki, Almeida, Hansel,
Muller, Souza, Machado-Vieira and Portela. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 June 2015 | Volume 9 | Article 219
